Loading...
Loading...
NVAX| Name | Value |
|---|---|
| Revenues | 22.1M |
| Cost of Revenue | 98.9M |
| Gross Profit | -76.9M |
| Operating Expense | 48.8M |
| Operating I/L | -125.6M |
| Other Income/Expense | -5.8M |
| Interest Income | 2.9M |
| Pretax | -131.5M |
| Income Tax Expense | -0.7M |
| Net Income/Loss | -130.8M |
Novavax, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of vaccines for infectious diseases. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine in Phase III trials, NanoFlu, a seasonal quadrivalent influenza vaccine in Phase 3 clinical trial, and ResVax, a respiratory syncytial virus (RSV) vaccine candidate. Novavax also has collaboration with Takeda Pharmaceutical for the development and commercialization of NVX-CoV2373. The company generates revenue through the development, manufacturing, and commercialization of its vaccine candidates.
